Theon targets €1bn in revenue in 2029

Backlog stood at about €1.4bn at the end of September. The aim is for products outside night vision to account for about 50% of revenue in the medium term. The Safran deal is expected to be signed in mid-December.

Theon targets €1bn in revenue in 2029

This article is an AI translation of an original piece published in Greek. Read original

Deliveries worth about €500m are scheduled by THEON for 2027 from its existing soft backlog, the group’s chief financial officer, Dimitris Parthenis, said during a presentation of the nine-month results to investors.

As he explained, the soft backlog, which includes signed contracts and secured orders, stood at about €1.4bn at the end of September. Including options, the total rises to about €2.3bn.

Mr Parthenis stressed that an increasing share of THEON’s order book comes from longer-term framework agreements. These give the group visibility on future revenue well beyond the usual 18-month horizon.

Diversifying the portfolio

Dimitris Parthenis stressed that THEON aims to establish a leading position in the wider defence optronics market comparable to the one it holds in night vision, by building a scalable platform to support the group’s long-term growth.

Further diversifying revenue streams is central to the group’s strategy. Night vision remains THEON’s core business and a significant growth driver. At the same time, the group is expanding into high-growth areas through its digital man-portable systems and enhanced capabilities in Intelligence, Surveillance and Reconnaissance (ISR).

By 2029, THEON aims to reach €1bn in annual revenue, through organic growth and the contribution of the complementary acquisitions it has already announced.

In the medium term, it aims for products outside night vision, including ISR solutions and digital man-portable systems, to contribute about 50% of total revenue, up from about 20% today.

“This transformation will be underpinned by continued investment in research and development (R&D), the introduction of new technologies and targeted bolt-on acquisitions that strengthen our existing capabilities.

It is important to stress that we are not moving away from night vision. We intend to maintain our global leadership in this market while building a more diversified business, with multiple growth drivers and the ability to serve a significantly larger market,” Mr Parthenis said.

Nine-month performance and outlook

On financial performance, Mr Parthenis said THEON had delivered another strong nine months, maintaining momentum across its operations and combining high growth with profitability among the highest in the sector.

As previously reported, in the nine months to September the group’s revenue rose 37.1% to €382.8m, while adjusted operating profit (EBIT) increased 44.4% to €100.2m. In the third quarter, revenue rose 40.4% to €134.1m, while adjusted operating profit increased 59.5% to €35.1m.

For 2026, the company is targeting revenue of about €600m, compared with €443m in 2025, and an adjusted EBIT margin of at least 26%.

The group’s chief financial officer stressed that THEON had raised its medium-term target for organic revenue growth, from more than 15% to more than 20% a year. The new target is underpinned by continued demand for night-vision products, a broader portfolio and growth prospects in the wider defence optronics market.

Safran joint venture and new Athens facility

On the group’s strategic partnerships, Mr Parthenis said the agreement with Safran to establish a joint venture is expected to be signed in mid-December. The venture will be based in France and have a presence in Germany, with production capabilities in Athens. It will focus on cameras for Type 1 and 2 drones (drones weighing less than 8kg, cameras weighing less than 1.5kg), with the aim of addressing a gap that management sees in the European market.

Regarding THEON’s new facility in Athens, Mr Parthenis said it remains scheduled to begin operations in the second quarter of 2027. The facility will strengthen the group’s production capabilities in ISR products.

HGH acquisition and priorities for 2027

Alongside strategic partnerships, Mr Parthenis also discussed the progress of the group’s acquisitions. As he noted, THEON has already completed its acquisition of MERIO. The group also received final regulatory approvals for its acquisition of HGH two days before the presentation and expects to complete the transaction in December 2026.

The group’s chief financial officer described the HGH acquisition as an important step in broadening THEON’s capabilities in multi-domain ISR and counter-drone solutions.

He said the deal accelerates the group’s entry into high-growth areas, particularly platform-based systems and the rapidly growing drone market.

It is worth recalling that the group has secured a new syndicated credit facility of up to €325m to finance the HGH acquisition, while maintaining its financial flexibility.

Finally, responding to a question on the subject, Mr Parthenis said THEON is not planning any further mergers and acquisitions (M&A), at least in 2027. After three acquisitions in 2026, the group’s priority is to integrate the companies it has acquired and realise synergies from those deals.

v
Privacy